TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03599089
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV administered intraoperatively
Study: NCT01760252
Drug: Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
Study: NCT00462501
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00462501
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02784899
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.
Study: NCT04454918
Drug: [14C]-TAK-906 Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-TAK-906 intravenous infusion.
Study: NCT04454918
Drug: [14C]-TAK-906 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-TAK-906 oral solution.
Study: NCT03551561
Drug: CSAC
Normalized name: Calcium Sucrose Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
Study: NCT02314819
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT00973804
Drug: EPOCH-F/R
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00973804
Drug: Transplant Preparative Regimen (Flu/Cy/Mes)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02504151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01177371
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01177371
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04616456
Drug: [F-18]PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT01774396
Drug: Emervel® Touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emervel® Touch will be injected only in the intervention group.
Study: NCT01702649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day.
Study: NCT02034227
Drug: SG2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
Study: NCT02995239
Drug: CJ-12420 formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJ-12420 formulation 2
Study: NCT03739203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied in capsules
Study: NCT03739203
Drug: Antidepressant Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT as prescribed by the physician per standard of care in clinical practice.
Study: NCT01935206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01729559
Drug: 5000 Units unfractionated Heparin Q 8 hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous thromboembolic prophylaxis medication
Study: NCT01077076
Drug: Prilosec OTC™ Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilosec OTC™ Tablets taken once daily for 11 days.
Study: NCT00561509
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use within normal clinical practice
Study: NCT04148846
Drug: Dypirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
Study: NCT02116309
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04148846
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
Study: NCT04148846
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally
Study: NCT03292731
Drug: Safety study of 500 mg dose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to 250 mg or 500 mg dose
Study: NCT03478982
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose for inhalation
Study: NCT00171561
Drug: valsartan/hydrochlorothiazide
Normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03773276
Drug: Norepinephrine boluses
Approvals — FDA: no, EMA: no, PMDA: no
Description: On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.
Study: NCT04145518
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
Study: NCT01721044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01721044
Drug: cDMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to take background cDMARD therapy throughout study.
Study: NCT01499355
Drug: oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study: NCT00003469
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT02668653
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02668653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01017198
Drug: BIIB0121 and Antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessing the effect of antacid use on BIIB021
Study: NCT02639221
Drug: PXT002331
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02565108
Drug: GWP42003-P 20 mg/kg/Day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT02565108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT02535806
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal dose For CNS negative patients, Day 1 and Day 8
Study: NCT02535806
Drug: Methotrexate / Hydrocortisone / Cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
Study: NCT02936596
Drug: Ursodeoxycholic acid combination of immunosuppressive agents
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
Study: NCT00433368
Drug: L-Ornithine L-Aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01005810
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules twice daily for 8 weeks
Study: NCT02708186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, matching tablets
Study: NCT00068419
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02282514
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Study: NCT01804127
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
Study: NCT00848965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01510704
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01510704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01237197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
Study: NCT04388254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral tablets
Study: NCT00404612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO BID
Study: NCT03358407
Drug: GSK2983559
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
Study: NCT03358407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.
Study: NCT04624295
Drug: Non-Early aspirin Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Study: NCT01017302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutenaous once weekly for 4 weeks
Study: NCT01017302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose in week 5
Study: NCT01017302
Drug: RO5095932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating subcutaneous doses once weekly over a 4 weeks period
Study: NCT01017302
Drug: RO5095932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutenaous dose in week 5
Study: NCT00224640
Drug: Iron chelating intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelating intervention
Study: NCT02015910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimick Sitagliptin 100mg pill.
Study: NCT00699114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose as powder in gelatine capsules, single dose
Study: NCT00699114
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg as powder in gelatine capsules, single dose
Study: NCT00699114
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg as powder in gelatine capsules, single dose
Study: NCT00699114
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800 mg as powder in gelatine capsules, single dose
Study: NCT00699114
Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
Study: NCT02490865
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60, 4 ml dose nebulized twice daily
Study: NCT02490865
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, 4 ml dose nebulized twice daily
Study: NCT00648765
Drug: Agrylin® Capsules 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg, single dose fed
Study: NCT02785523
Drug: Ganoderma Spore Lipids
Normalized name: Ganoderma lucidum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02785523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02785523
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00654550
Drug: Nexagon™ or Nexagon™ vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
Study: NCT02503137
Drug: Topical SM04554 solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02094157
Drug: Bridged regimen Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is assigned to the active control arm - Bridged regimen
Study: NCT00933543
Drug: Visonac PDT (MAL PDT)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream application followed by illumination with red light.
Study: NCT04257929
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT03427320
Drug: [131]I-IAZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
Study: NCT01744106
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01209689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02506348
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02506348
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02353273
Drug: WH-1 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
Study: NCT04190966
Drug: Integrated Pharmacotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
Study: NCT04179669
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02644499
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
Study: NCT02644499
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
Study: NCT02644499
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Study: NCT01054885
Drug: FF/GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study: NCT01054885
Drug: GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Acting Beta Agonist(LABA)
Study: NCT01054885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00479427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00807001
Drug: IDX184
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose, active or placebo
Study: NCT04004195
Drug: BAY2327949
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
Study: NCT02417506
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06343480
Drug: Labour Induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: the use of misoprostol sublingual for labour induction compared with oxytocin titration in parturients with prelabour membrane rupture at term.
Study: NCT01429740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution or capsules
Study: NCT04057573
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT00696631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00712439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00068692
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00068692
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03570710
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Study: NCT04683614
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mic/kg/hr norepinephrine
Study: NCT02583594
Drug: Ceterizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04510818
Drug: Capecitabine, Camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single-arm study with all patients receiving these two drugs.
Study: NCT02850913
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety
Study: NCT00331097
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 intravenously days 1, 8 every 28 days
Study: NCT00331097
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m2 intravenously days 1 and 8 every 28 days
Study: NCT02298010
Drug: Capecitabine, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00914316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT00543413
Drug: MK8141
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
Study: NCT00543413
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK8141 Pbo tablet once daily. 4 week treatment period.
Study: NCT03349034
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Study: NCT03349034
Drug: Local Saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Study: NCT01737437
Drug: group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
Study: NCT01737437
Drug: group LV
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Lidocaine was applied on laryngoscope blade and trachea.
Study: NCT03848832
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P presented as an oral solution containing cannabidiol
Study: NCT03848832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral solution
Study: NCT03723772
Drug: IGlar U100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.